Comparing Journey Medical (NASDAQ:DERM) & Synaptogenix (NASDAQ:TAOX)
by Michael Walen · The Markets DailySynaptogenix (NASDAQ:TAOX – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.
Analyst Ratings
This is a breakdown of recent recommendations for Synaptogenix and Journey Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Synaptogenix | 1 | 0 | 0 | 0 | 1.00 |
| Journey Medical | 1 | 1 | 2 | 0 | 2.25 |
Journey Medical has a consensus price target of $14.00, indicating a potential upside of 111.64%. Given Journey Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Journey Medical is more favorable than Synaptogenix.
Volatility & Risk
Synaptogenix has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
Earnings and Valuation
This table compares Synaptogenix and Journey Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Synaptogenix | $300,000.00 | 111.93 | -$28.74 million | ($3.85) | -1.17 |
| Journey Medical | $61.86 million | 3.02 | -$11.43 million | ($0.22) | -30.07 |
Journey Medical has higher revenue and earnings than Synaptogenix. Journey Medical is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Synaptogenix and Journey Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Synaptogenix | -2,153.97% | -128.51% | -97.54% |
| Journey Medical | -8.95% | -20.23% | -6.60% |
Insider & Institutional Ownership
10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 7.2% of Journey Medical shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Journey Medical beats Synaptogenix on 10 of the 14 factors compared between the two stocks.
About Synaptogenix
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
About Journey Medical
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.